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Most cancer cells in culture express
increased levels of components of the
insulin-like growth factor (IGF) system,
especially IGF-2, and the type 1 IGF
receptor (IGF-1R), a receptor tyrosine
kinase that mediates both mitogenic 
and antiapoptotic pathways (Figure 1).
Investigators have therefore surmised
that the IGF system, and perhaps the
IGF-1R in particular, may be an appropri-
ate target for inhibition of cancer cell
growth (LeRoith et al., 1995). Further evi-
dence suggesting the importance of the
IGF-1R pathway in cancer includes the
finding that a variety of oncogenes
require an intact IGF-1R for transforming
activity (Sell et al., 1994; Toretsky et al.,
1997). The link between cancer and IGF
signaling is also consistent with recent
epidemiological studies showing an
increased relative risk for the develop-
ment of colon, prostate, breast, lung, and
bladder cancers in individuals with circu-
lating IGF-1 levels in the upper tertile of
the normal range (Chan et al., 1998).
These findings were confirmed in animal
models, where reduced circulating IGF-1
levels result in significant reductions 
in cancer development, growth, and
metastases, whereas increased circulat-
ing IGF-1 levels are associated with
enhanced tumor growth (Wu et al., 2003).
It is also notable that while no specific
mutations in IGF receptors or ligands
have been identified in cancers, there is
clear evidence of epigenetic alterations—
i.e., loss of imprinting (LOI) of IGF-2 in a
variety of human tumors (Rainier et al.,
1993; Zhan et al., 1994). Taken together,
the data provide strong evidence for a
critical link between IGF signaling and
human cancer.
Various attempts have been made to
inhibit the IGF system, which is com-
prised of two ligands, IGF-1 and IGF-2,
six IGF binding proteins (IGFBPs-1
through -6), and the IGF-1R, which
mediates most of the cellular signaling
functions of this system (Firth and
Baxter, 2002).Table 1 lists some of these
approaches, including suppression of
circulating IGF-1 and monoclonal anti-
bodies that neutralize IGF-1.
Studies in cell culture systems
demonstrated that inhibition of IGF-1R
expression or activation successfully
inhibited cancer cell growth and colony
formation, whereas overexpression can
transform certain cells, suggesting that
similar effects may be reproduced in vivo
(Butler et al., 1998).The IGF-1R has been
successfully inhibited in rodents using a
variety of molecules. When antisense
oligonucleotides were injected intraperi-
toneally, the growth of human cancers
was inhibited in nude mice, and similar
effects were observed with the mouse
monoclonal antibody α IR3 (Table 1).
However, these approaches have numer-
ous problems, including lack of specificity,
difficulty of drug delivery, etc. Inhibition of
IGF-I levels, while useful in mice, probably
will not be useful in humans, who also
have high circulating levels of IGF-2,
which can also activate the IGF-1R.
More recently, investigators have
determined that inhibition of the tyrosine
kinase domain of a particular receptor
may be a better approach, particularly if a
small molecule can be found that specifi-
cally inhibits a particular kinase. This
approach has already been successful,
most notably with the development of ima-
tinib mesylate, an inhibitor of the BCR-
ABL fusion kinase expressed in CML
cells, as well as the c-kit kinase, which is
mutated in GIST tumors. This drug exhib-
ited considerable activity in the treatment
of these tumors (Heinrich et al., 2003).
In this issue of Cancer Cell, two
articles describe the inhibition of IGF-1R
signaling cascades by a small molecule
kinase inhibitor of the pyrrolo[2,3-d]pyrim-
idine class, discovered by high-through-
put screening of molecules that inhibit
IGF-1R activity (García-Echeverría et al.,
2004; Mitsiades et al., 2004). In the first
study (García-Echeverría et al., 2004),
NVP-AEW541 exhibited a similar IC50
toward the IGF-1R and insulin receptor
(IR) kinase domains in vitro; however,
there was a 27-fold higher affinity for the
native IGF-1R kinase in assays measur-
ing autophosphorylation of the receptor
as the end point. A much lower affinity
was demonstrated toward other tyrosine
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The insulin-like growth factors (IGF) system, and particularly the IGF-1 receptor, has recently become the subject of major
interest in the arena of cancer research. Its involvement in cancer cell growth and survival makes the system an excellent
target as potential adjunct therapy to standard chemotherapy.
Figure 1. Schematic of the IGF system
Extracellular IGFs bind to the IGF-1R and the activated tyrosine kinase leads to enhanced cell
proliferation and cell survival mediated by signaling pathways that include the PI3′ kinase/Akt
and the MAPK pathways. Inhibition of the IGF-1R may occur at multiple levels both extracellular
and intracellular.
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kinases, suggesting that this is a fairly
specific molecule. Inhibition of the IGF-
1R tyrosine kinase was also associated
with inhibition of both the PI3′K and
MAPK signaling pathways, in response to
IGF-1 stimulation of cells in culture. Both
of these pathways are critical for the anti-
apoptotic and mitogenic effects, which
were inhibited. Mouse 3T3 fibroblasts
overexpressing the human IGF-1R form
tumors in nude mice, and subcutaneous
injection of NVP-AEW541 inhibited the
growth of these tumors.
The second study focuses on the
effect of a similar second small molecule
(NVP-ADW742) on hematologic malig-
nancies, especially multiple myeloma
(Mitsiades et al., 2004). This molecule
also demonstrates a >16-fold greater
potency against the IGF-1R, as com-
pared to the insulin receptor, and was
similarly effective in inhibiting cell growth
and survival. When injected intraperi-
toneally, NVP-ADW742 inhibited multiple
myeloma cell growth and enhanced sur-
vival of the mice. Importantly, when com-
bined with Melphalan at subtherapeutic
doses, the two compounds synergistical-
ly reduced tumor burden.
These studies prove that inhibition of
the IGF-1R tyrosine kinase activity by
small molecules is possible, and suggest
that this approach may be useful in the
treatment of human cancer. However,
many questions remain to be answered:
(1) How should tumors be screened
as candidates for treatment using this
approach? As noted above, there are no
examples of genetic alterations of this
pathway in human tumors, so it is
unclear how tumors should be selected
for treatment. Is activation of the recep-
tor in a tumor likely to predict respon-
siveness? Are tumors with LOI of IGF-2
likely to respond?
(2) Would small molecule therapy be
used together with chemotherapy or
between courses? Could this approach
be more active if combined with kinase
inhibitors targeting downstream mole-
cules of the IGF-1R? Most chemothera-
peutic regimens are cytotoxic, and the
recurrences are assumed to be due to
proliferation of cells that the chemothera-
py failed to eradicate. These cells could
potentially be killed off by the IGF-1R
tyrosine kinase inhibitors.
(3) What effects may the inhibitors
have on IGF-1Rs in normal tissues and
even on the insulin receptor? While the
small molecules described here have a
16- to 27-fold lower affinity for the IGF-
1R than the insulin receptor, the relative
affinities in patients and on different tis-
sues remain unknown. It is hoped that
intermittent therapy with these or similar
agents may have minimal effects, per-
haps only on tissues that demonstrate a
high level of cellular turnover such as the
bone marrow and gastrointestinal tract.
These side effects may therefore be sim-
ilar to those seen with chemotherapy and
may be limited in extent and duration;
clinical trials will be required to establish
this. Regarding the insulin receptor,
intermittent therapy may worsen insulin
resistance and diabetes, which may be
limited and easily treatable.
(4) Would these IGF-1R tyrosine
kinase inhibitors be useful as chemopre-
ventive agents?
Despite the numerous unanswered
questions, the findings in these two stud-
ies represent a major advance in this
area of research. They strongly support
the contention that blockade of the IGF-
1R may be an important form of adjunct
therapy for cancer patients. It may
reduce side effects by lowering the
doses of chemotherapeutic agents, and
perhaps making chemotherapy more
effective, thereby increasing “cures” or
remission rates and intervals. Whether
the agent used is a humanized antibody,
small peptide inhibitor, or small molecule
(as described in these studies), it is
becoming clear that the IGF system
plays a critical role in the development
and treatment of cancer.
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Table 1. Inhibitors of the IGF-1R
1. Blockade of IGF binding
a. Antibody to IGF-1, antibody to the IGF-1R (α IR3)1
b. Inhibitors of ligand binding; D amino acid analog of IGF-12
c. Inhibitory IGF binding proteins3
2. Reduction of IGF-IR expression
a. Targeting of IGF-1R-expressing cells using IGF-1 fused to pseudomona exotoxin cytotoxic domain4
b. Antisense to the IGF-1R, through either oligonucleotides, stable transfections, or siRNAs5,6
3. Inhibition of IGF-1R function
a. Dominant negative IGF-1R inhibits receptors of receptor function7
b. Small molecule inhibition of the IGF-1R tyrosine kinase activity8
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